PDF herunterladen
CC BY 4.0 · Glob Med Genet 2022; 09(04): 277-286
DOI: 10.1055/s-0042-1758204
Original Article

Exosomal microRNAs Targeting TP53 Gene as Promising Prognostic Markers for Head and Neck Squamous Cell Carcinoma

Vijayashree Priyadharsini Jayaseelan 
1   Clinical Genetics Lab, Centre for Cellular and Molecular Research, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Saveetha Dental College and Hospital, Chennai, Tamil Nadu, India
,
Paramasivam Arumugam 
2   Molecular Biology Lab, Centre for Cellular and Molecular Research, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Saveetha Dental College and Hospital, Chennai, Tamil Nadu, India
› Institutsangaben Funding The authors V.P.J. and P.A. thank the Science and Engineering Research Board (SERB), Government of India for the financial support rendered through the core research grant (CRG) (No. CRG/2019/003756) and (EEQ) (No.EEQ/2019/000411).
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Statement of Problem MicroRNAs are small non-coding RNAs that regulate an array of functions by targeting crucial genes. A significant dysregulation in the TP53 profile has been observed in the head and neck squamous cell carcinoma (HNSCC) patients. Hence, the present in silico study was designed to identify those microRNAs which target TP53 gene and demonstrate their differential expression in HNSCC cases.

Materials and Methods The study was extended further to explore their exosomal location using database such as EVmiRNA and ExoCarta. The study follows an observational in silico design. Computational tool miRDB was used identify the microRNA targets of TP53 gene. The UALCAN server was used to ascertain the expression of microRNA in HNSCC cases derived from the Cancer Gene Atlas dataset. The survival of HNSCC patients based on the differential expression microRNA markers were recorded. Further, each of the microRNA was queried for their exosomal presence using EVmiRNA.

Results About 102 microRNA targets of TP53 gene with a target score in the range of 95–50 were identified. The differential expression data for 52 microRNAs was retrieved from the UALCAN database. The microRNAs hsa-miR-421, hsa-miR-548f-5p, and hsa-let-7c-5p were found to be differentially expressed with marked influence over the survival of HNSCC patients. Furthermore, hsa-miR-421 and hsa-let-7c-5p were found to have an exosomal origin especially in body fluids such as blood and saliva.

Conclusion The results accumulated from the present study identified three microRNAs which can affect the functions of TP53 gene and bring about serious outcomes in HNSCC patients. The microRNAs of exosomal origin targeting TP53 gene in HNSCC patients can be a promising prognostic marker, which can be further used as a therapeutic lead by designing inhibitors.

Keywords

microRNAs - exosomes - TP53 - HNSCC - theragnostic

Authors' Contribution

V.P.J. did the conceptualization, worked on analysis and results, and interpretation and manuscript writing. P.A. did the study design, cross-valuation of results, manuscript writing, formatting and editing, and overall supervision.


Ethics Approval

Not applicable.


Informed Consent

Not applicable.




Publikationsverlauf

Eingereicht: 17. August 2022

Angenommen: 30. August 2022

Artikel online veröffentlicht:
14. Dezember 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71 (03) 209-249
    Google Scholar
  • 2 Ram H, Sarkar J, Kumar H, Konwar R, Bhatt ML, Mohammad S. Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg 2011; 10 (02) 132-137
    CrossrefPubMedGoogle Scholar
  • 3 Klinakis A, Rampias T. TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection. EBioMedicine 2020; 58: 102905
    CrossrefPubMedGoogle Scholar
  • 4 Chou ST, Peng HY, Mo KC. et al. MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1. J Exp Clin Cancer Res 2019; 38 (01) 281
    CrossrefPubMedGoogle Scholar
  • 5 Jayaseelan VP. Emerging role of exosomes as promising diagnostic tool for cancer. Cancer Gene Ther 2020; 27 (06) 395-398
    CrossrefPubMedGoogle Scholar
  • 6 Cerami E, Gao J, Dogrusoz U. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2 (05) 401-404
    CrossrefPubMedGoogle Scholar
  • 7 Gao J, Aksoy BA, Dogrusoz U. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6 (269) pl1
    PubMedGoogle Scholar
  • 8 Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res 2015; 43 (Database issue): D146-D152
    CrossrefPubMedGoogle Scholar
  • 9 Liu W, Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol 2019; 20 (01) 18
    CrossrefPubMedGoogle Scholar
  • 10 Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res 2020; 48 (D1): D127-D131
    CrossrefPubMedGoogle Scholar
  • 11 Chandrashekar DS, Bashel B, Balasubramanya SAH. et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia 2017; 19 (08) 649-658
    CrossrefPubMedGoogle Scholar
  • 12 Liu T, Zhang Q, Zhang J. et al. EVmiRNA: a database of miRNA profiling in extracellular vesicles. Nucleic Acids Res 2019; 47 (D1): D89-D93
    CrossrefPubMedGoogle Scholar
  • 13 Keerthikumar S, Chisanga D, Ariyaratne D. et al. ExoCarta: A Web-Based Compendium of Exosomal Cargo. J Mol Biol 2016; 428 (04) 688-692
    CrossrefPubMedGoogle Scholar
  • 14 Simpson RJ, Kalra H, Mathivanan S. ExoCarta as a resource for exosomal research. J Extracell Vesicles 2012; 1: 1
    CrossrefPubMedGoogle Scholar
  • 15 Mathivanan S, Simpson RJ. ExoCarta: A compendium of exosomal proteins and RNA. Proteomics 2009; 9 (21) 4997-5000
    CrossrefPubMedGoogle Scholar
  • 16 Nohata N, Hanazawa T, Kinoshita T, Okamoto Y, Seki N. MicroRNAs function as tumor suppressors or oncogenes: aberrant expression of microRNAs in head and neck squamous cell carcinoma. Auris Nasus Larynx 2013; 40 (02) 143-149
    CrossrefPubMedGoogle Scholar
  • 17 Kinoshita T, Hanazawa T, Nohata N, Okamoto Y, Seki N. The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways. J Hum Genet 2012; 57 (09) 556-563
    CrossrefPubMedGoogle Scholar
  • 18 Jayaseelan VP, Arumugam P. Exosomal microRNAs as a promising theragnostic tool for essential hypertension. Hypertens Res 2020; 43 (01) 74-75
    CrossrefPubMedGoogle Scholar
  • 19 Jayaseelan VP, Arumugam P. Dissecting the theranostic potential of exosomes in autoimmune disorders. Cell Mol Immunol 2019; 16 (12) 935-936
    CrossrefPubMedGoogle Scholar
  • 20 Soares Martins T, Marçalo R, Ferreira M. et al. Exosomal Aβ-Binding Proteins Identified by “In Silico” Analysis Represent Putative Blood-Derived Biomarker Candidates for Alzheimeŕs Disease. Int J Mol Sci 2021; 22 (08) 3933
    CrossrefPubMedGoogle Scholar
  • 21 Koshizuka K, Hanazawa T, Arai T, Okato A, Kikkawa N, Seki N. Involvement of aberrantly expressed microRNAs in the pathogenesis of head and neck squamous cell carcinoma. Cancer Metastasis Rev 2017; 36 (03) 525-545
    CrossrefPubMedGoogle Scholar
  • 22 Wang R, Fang J, Ma H. et al. Effect of microRNA-203 on tumor growth in human hypopharyngeal squamous cell carcinoma. Mol Cell Biochem 2015; 405 (1-2): 97-104
    CrossrefPubMedGoogle Scholar
  • 23 Li H, Wang F, Fei Y. et al. Aberrantly expressed genes and miRNAs in human hypopharyngeal squamous cell carcinoma based on RNA–sequencing analysis. Oncol Rep 2018; 40 (02) 647-658
    PubMedGoogle Scholar
  • 24 Ganci F, Sacconi A, Bossel Ben-Moshe N. et al. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann Oncol 2013; 24 (12) 3082-3088
    CrossrefPubMedGoogle Scholar
  • 25 El Baroudi M, Machiels JP, Schmitz S. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck. Cancer Biol Ther 2017; 18 (10) 775-782
    CrossrefPubMedGoogle Scholar
  • 26 Koshizuka K, Hanazawa T, Kikkawa N. et al. Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma. Auris Nasus Larynx 2018; 45 (04) 854-865
    CrossrefPubMedGoogle Scholar
  • 27 Ji Y, Feng G, Hou Y, Yu Y, Wang R, Yuan H. Long noncoding RNA MEG3 decreases the growth of head and neck squamous cell carcinoma by regulating the expression of miR-421 and E-cadherin. Cancer Med 2020; 9 (11) 3954-3963
    CrossrefPubMedGoogle Scholar
  • 28 Chen PY, Hsieh PL, Peng CY, Liao YW, Yu CH, Yu CC. LncRNA MEG3 inhibits self-renewal and invasion abilities of oral cancer stem cells by sponging miR-421. J Formos Med Assoc 2021; 120 (04) 1137-1142
    CrossrefPubMedGoogle Scholar
  • 29 Wu Q, Liu P, Lao G, Liu Y, Zhang W, Ma C. Comprehensive Analysis of circRNA-miRNA-mRNA Network in Cervical Squamous Cell Carcinoma by Integrated Analysis. OncoTargets Ther 2020; 13: 8641-8650
    CrossrefPubMedGoogle Scholar
  • 30 Yu DH, Ruan XL, Huang JY. et al. Analysis of the Interaction Network of Hub miRNAs-Hub Genes, Being Involved in Idiopathic Pulmonary Fibers and Its Emerging Role in Non-small Cell Lung Cancer. Front Genet 2020; 11: 302
    CrossrefPubMedGoogle Scholar
  • 31 Knyazev EN, Fomicheva KA, Mikhailenko DS. et al. Plasma Levels of hsa-miR-619-5p and hsa-miR-1184 Differ in Prostatic Benign Hyperplasia and Cancer. Bull Exp Biol Med 2016; 161 (01) 108-111
    CrossrefPubMedGoogle Scholar